# LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

> **NCT00859222** · PHASE1,PHASE2 · COMPLETED · sponsor: **Patrick Y. Wen, MD** · enrollment: 51 (actual)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** LBH589
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00859222
- **Lead sponsor:** Patrick Y. Wen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-09
- **Final completion:** 2015-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-03-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859222, "LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00859222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*